Profile - To The Moon

jimzephyr

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- jimzephyrjimzephyr
  ·2022-02-10
  DIS
  After-Hours Stock Movers: Disney, Uber, Twilio, Roku, 2U and more
  After-Hours Stock MoversTwilio (NYSE: TWLO) 19.5% HIGHER; reported Q4 EPS of ($0.20), $0.02 better t
  After-Hours Stock Movers: Disney, Uber, Twilio, Roku, 2U and more
  342 Comment
  2
  Share
  Report
- jimzephyrjimzephyr
  ·2021-04-28
  Nice, let it keep going up
  AMD rose more than 3% in premarket trading
  AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by
  AMD rose more than 3% in premarket trading
  266 Comment
  Like
  Share
  Report
- jimzephyrjimzephyr
  ·2021-04-15
  Interesting
  Merck ends development of Covid drug it acquired from OncoImmune
  KEY POINTS Merck announced Thursday it will end the development of a Covid-19 drug it acquired from
  Merck ends development of Covid drug it acquired from OncoImmune
  93 Comment
  1
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3567332724919443","uuid":"3567332724919443","gmtCreate":1604302960444,"gmtModify":1618496626346,"name":"jimzephyr","pinyin":"jimzephyr","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9096456669,"gmtCreate":1644452593367,"gmtModify":1676533927798,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"themes":[],"htmlText":"DIS","listText":"DIS","text":"DIS","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096456669","repostId":"2210563400","repostType":2,"repost":{"id":"2210563400","kind":"news","pubTimestamp":1644450000,"share":"https://ttm.financial/m/news/2210563400?lang=&edition=fundamental","pubTime":"2022-02-10 07:40","market":"us","language":"en","title":"After-Hours Stock Movers: Disney, Uber, Twilio, Roku, 2U and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2210563400","media":"StreetInsider","summary":"After-Hours Stock MoversTwilio (NYSE: TWLO) 19.5% HIGHER; reported Q4 EPS of ($0.20), $0.02 better t","content":"<html><head></head><body><p>After-Hours Stock Movers</p><p>Twilio (NYSE: TWLO) 19.5% HIGHER; reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $842.7 million versus the consensus estimate of $767.83 million. Twilio sees Q1 2022 EPS of ($0.26)-($0.22), versus the consensus of ($0.05). Twilio sees Q1 2022 revenue of $855-865 million, versus the consensus of $802.9 million.</p><p>Vimeo (NASDAQ: VMEO) 19.4% LOWER; reported Q4 EPS of ($0.05), $0.03 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $106.1 million versus the consensus estimate of $104.94 million. FY 22 Revenue growth of 17% to 19% year-over-year.</p><p>Marqeta (NASDAQ: MQ) 15.7% HIGHER; announced the appointment of Mike Milotich as the company&#39;s new Chief Financial Officer, effective February 22, 2022. Raises Q4 outlook.</p><p>2u (NASDAQ: TWOU) 20.4% LOWER; reported Q4 EPS of ($0.20), $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $243.6 million versus the consensus estimate of $243 million.</p><p>Seagen (NASDAQ: SGEN) 16.6% LOWER; reported Q4 EPS of ($0.95), $0.13 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $369.2 million versus the consensus estimate of $406.87 million. Seagen sees FY2022 revenue of $1.48-1.545 billion, versus the consensus of $2.16 billion.</p><p><a href=\"https://laohu8.com/S/APTS\">Preferred Apartment Communities</a> (NYSE: APTS) 15.2% HIGHER; is exploring options including a full or partial sale after receiving interest, according to Bloomberg, citing people with knowledge of the matter.</p><p>Mattel (NASDAQ: MAT) 9.5% HIGHER; reported Q4 EPS of $0.53, $0.23 better than the analyst estimate of $0.30. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.65 billion. Mattel sees FY2022 EPS of $1.42-$1.48, versus the consensus of $1.39. Sees revenue up 8-10%.</p><p>Walt Disney (NYSE: DIS) 6.8% HIGHER; reported Q1 EPS of $1.06, $0.42 better than the analyst estimate of $0.64. Revenue for the quarter came in at $21.82 billion versus the consensus estimate of $18.78 billion.</p><p>Uber (NYSE: UBER) 5.5% HIGHER; reported Q4 EPS of $0.44, $0.79 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.34 billion.</p><p>Roku, Inc. (NASDAQ: ROKU) 3.1% HIGHER; gains following Disney results.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Disney, Uber, Twilio, Roku, 2U and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Disney, Uber, Twilio, Roku, 2U and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-10 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19586772><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock MoversTwilio (NYSE: TWLO) 19.5% HIGHER; reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $842.7 million versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19586772\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWOU":"2U Inc","BK4190":"消闲用品","MAT":"美国美泰公司","UBER":"优步","BK4204":"教育服务","BK4215":"住宅房地产投资信托","MQ":"Marqeta, Inc.","SGEN":"Seagen","TWLO":"Twilio Inc","BK4116":"互联网服务与基础架构","VMEO":"Vimeo Inc.","BK4077":"互动媒体与服务","APTS":"Preferred Apartment Communities","BK4139":"生物科技","DIS":"迪士尼"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19586772","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210563400","content_text":"After-Hours Stock MoversTwilio (NYSE: TWLO) 19.5% HIGHER; reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $842.7 million versus the consensus estimate of $767.83 million. Twilio sees Q1 2022 EPS of ($0.26)-($0.22), versus the consensus of ($0.05). Twilio sees Q1 2022 revenue of $855-865 million, versus the consensus of $802.9 million.Vimeo (NASDAQ: VMEO) 19.4% LOWER; reported Q4 EPS of ($0.05), $0.03 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $106.1 million versus the consensus estimate of $104.94 million. FY 22 Revenue growth of 17% to 19% year-over-year.Marqeta (NASDAQ: MQ) 15.7% HIGHER; announced the appointment of Mike Milotich as the company's new Chief Financial Officer, effective February 22, 2022. Raises Q4 outlook.2u (NASDAQ: TWOU) 20.4% LOWER; reported Q4 EPS of ($0.20), $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $243.6 million versus the consensus estimate of $243 million.Seagen (NASDAQ: SGEN) 16.6% LOWER; reported Q4 EPS of ($0.95), $0.13 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $369.2 million versus the consensus estimate of $406.87 million. Seagen sees FY2022 revenue of $1.48-1.545 billion, versus the consensus of $2.16 billion.Preferred Apartment Communities (NYSE: APTS) 15.2% HIGHER; is exploring options including a full or partial sale after receiving interest, according to Bloomberg, citing people with knowledge of the matter.Mattel (NASDAQ: MAT) 9.5% HIGHER; reported Q4 EPS of $0.53, $0.23 better than the analyst estimate of $0.30. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.65 billion. Mattel sees FY2022 EPS of $1.42-$1.48, versus the consensus of $1.39. Sees revenue up 8-10%.Walt Disney (NYSE: DIS) 6.8% HIGHER; reported Q1 EPS of $1.06, $0.42 better than the analyst estimate of $0.64. Revenue for the quarter came in at $21.82 billion versus the consensus estimate of $18.78 billion.Uber (NYSE: UBER) 5.5% HIGHER; reported Q4 EPS of $0.44, $0.79 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.34 billion.Roku, Inc. (NASDAQ: ROKU) 3.1% HIGHER; gains following Disney results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100815154,"gmtCreate":1619599033278,"gmtModify":1704726569578,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"themes":[],"htmlText":"Nice, let it keep going up","listText":"Nice, let it keep going up","text":"Nice, let it keep going up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/100815154","repostId":"1186026456","repostType":4,"repost":{"id":"1186026456","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619597271,"share":"https://ttm.financial/m/news/1186026456?lang=&edition=fundamental","pubTime":"2021-04-28 16:07","market":"us","language":"en","title":"AMD rose more than 3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186026456","media":"Tiger Newspress","summary":"AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by ","content":"<p>AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by 93% year-on-year.</p><p><img src=\"https://static.tigerbbs.com/3233ac832ae2bb19ac73d8f51a84537d\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><b>AMD Earnings, Revenue Beat in Q1</b></p><p>AMD reported on Tuesday first quarterearningsthat beat analysts' forecasts and revenue that topped expectations.</p><p>AMD announced earnings per share of $0.52 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $0.4357 on revenue of $3.18B.</p><p>AMD shares are up 10% from the beginning of the year, still down 14.11% from its 52 week high of $99.21 set on January 11. They are under-performing the Dow Jones which is up 11.04% from the start of the year.</p><p>AMD follows other major Technology sector earnings this month</p><p>AMD's report follows an earnings beat by Microsoft on Tuesday, who reported EPS of $1.95 on revenue of $41.71B, compared to forecasts EPS of $1.78 on revenue of $41.04B.</p><p>Alphabet C had beat expectations on Tuesday with first quarter EPS of $26.29 on revenue of $55.31B, compared to forecast for EPS of $15.71 on revenue of $51.36B.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD rose more than 3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD rose more than 3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-04-28 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by 93% year-on-year.</p><p><img src=\"https://static.tigerbbs.com/3233ac832ae2bb19ac73d8f51a84537d\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><b>AMD Earnings, Revenue Beat in Q1</b></p><p>AMD reported on Tuesday first quarterearningsthat beat analysts' forecasts and revenue that topped expectations.</p><p>AMD announced earnings per share of $0.52 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $0.4357 on revenue of $3.18B.</p><p>AMD shares are up 10% from the beginning of the year, still down 14.11% from its 52 week high of $99.21 set on January 11. They are under-performing the Dow Jones which is up 11.04% from the start of the year.</p><p>AMD follows other major Technology sector earnings this month</p><p>AMD's report follows an earnings beat by Microsoft on Tuesday, who reported EPS of $1.95 on revenue of $41.71B, compared to forecasts EPS of $1.78 on revenue of $41.04B.</p><p>Alphabet C had beat expectations on Tuesday with first quarter EPS of $26.29 on revenue of $55.31B, compared to forecast for EPS of $15.71 on revenue of $51.36B.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186026456","content_text":"AMD rose more than 3% in premarket trading.Q1 net profit exceeded expectations, and revenue rose by 93% year-on-year.AMD Earnings, Revenue Beat in Q1AMD reported on Tuesday first quarterearningsthat beat analysts' forecasts and revenue that topped expectations.AMD announced earnings per share of $0.52 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $0.4357 on revenue of $3.18B.AMD shares are up 10% from the beginning of the year, still down 14.11% from its 52 week high of $99.21 set on January 11. They are under-performing the Dow Jones which is up 11.04% from the start of the year.AMD follows other major Technology sector earnings this monthAMD's report follows an earnings beat by Microsoft on Tuesday, who reported EPS of $1.95 on revenue of $41.71B, compared to forecasts EPS of $1.78 on revenue of $41.04B.Alphabet C had beat expectations on Tuesday with first quarter EPS of $26.29 on revenue of $55.31B, compared to forecast for EPS of $15.71 on revenue of $51.36B.","news_type":1},"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347851905,"gmtCreate":1618487902807,"gmtModify":1704711578096,"author":{"id":"3567332724919443","authorId":"3567332724919443","name":"jimzephyr","avatar":"https://static.tigerbbs.com/0e06fb235e0a39bae550fa602632b2bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3567332724919443","authorIdStr":"3567332724919443"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347851905","repostId":"1183968578","repostType":4,"repost":{"id":"1183968578","kind":"news","pubTimestamp":1618487325,"share":"https://ttm.financial/m/news/1183968578?lang=&edition=fundamental","pubTime":"2021-04-15 19:48","market":"us","language":"en","title":"Merck ends development of Covid drug it acquired from OncoImmune","url":"https://stock-news.laohu8.com/highlight/detail?id=1183968578","media":"cnbc","summary":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from","content":"<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck ends development of Covid drug it acquired from OncoImmune</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck ends development of Covid drug it acquired from OncoImmune\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.cnbc.com/2021/04/15/merck-ends-development-of-covid-drug-it-acquired-from-oncoimmune.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1183968578","content_text":"KEY POINTS\n\nMerck announced Thursday it will end the development of a Covid-19 drug it acquired from biopharmaceutical company OncoImmune.\nMerck disclosed in February that U.S. regulators had asked for more data on the drug to support a potential emergency use authorization.\nDue to \"regulatory uncertainties\" and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug.\n\nMerckannounced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization.\nNew Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.\nAn interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.\nHowever, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.\nNow, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.\n“Based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022,” the company said in a press release.\nThe announcement marks another disappointment for Merck in efforts to combat the pandemic.\nIn January, it announced it wouldend the development of its two Covid-19 vaccines. In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from Covid-19 as well as those reported for other vaccines, according to the company.\nWhile Merck is discontinuing MK-7110, the company said it will move forward with its oral antiviral drug, molnupiravir, in a phase three clinical trial testing non-hospitalized patients with Covid-19.\n“We continue to make progress in the clinical development of our antiviral candidate molnupiravir,” Roy Baynes, Merck’s chief medical officer, said in a release. “Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}